Literature DB >> 16131995

Adalimumab, a novel anti-tumor necrosis factor-alpha antibody in a child with refractory Crohn's disease.

Sameera Mian1, Howard Baron.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16131995     DOI: 10.1097/01.mpg.0000169275.86308.b0

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


× No keyword cloud information.
  7 in total

1.  Efficacy and safety of adalimumab in Crohn's disease.

Authors:  Gary R Lichtenstein; Remo Panaccione; Gordon Mallarkey
Journal:  Therap Adv Gastroenterol       Date:  2008-07       Impact factor: 4.409

2.  Growth and bone health in paediatric patients with Crohn's disease receiving subcutaneous tumor necrosis factor antibody.

Authors:  Judith Pichler; Wolf Dietrich Huber; Christoph Aufricht; Bettina Bidmon-Fliegenschnee
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

3.  Adalimumab for the treatment of Crohn's disease.

Authors:  Andrea Cassinotti; Sandro Ardizzone; Gabriele Bianchi Porro
Journal:  Biologics       Date:  2008-12

Review 4.  Managing Crohn disease in children and adolescents : focus on tumor necrosis factor antagonists.

Authors:  Shehzad A Saeed; Wallace V Crandall
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

5.  Adalimumab treatment in children with refractory Crohn's disease.

Authors:  Yoram Rosenbach; Corina Hartman; Rivka Shapiro; Akiva Hirsch; Yaron Avitzur; Raanan Shamir
Journal:  Dig Dis Sci       Date:  2009-03-31       Impact factor: 3.199

Review 6.  TNF blocking therapies and immunomonitoring in patients with inflammatory bowel disease.

Authors:  Romain Altwegg; Thierry Vincent
Journal:  Mediators Inflamm       Date:  2014-03-18       Impact factor: 4.711

Review 7.  Difficult-to-treat-pediatric Crohn's disease: focus on adalimumab.

Authors:  Bella Zeisler; Jeffrey S Hyams
Journal:  Pediatric Health Med Ther       Date:  2015-04-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.